loading page

ε-Aminocaproic acid (EACA) vs. tranexamic acid (TXA) in children undergoing complex cranial vault reconstruction for repair of craniosynostosis
  • +4
  • Alexandra Borst,
  • Christopher Bonfield,
  • Poornachanda Deenadayalan,
  • Chi Le,
  • Meng Xu,
  • Jenna Sobey,
  • Srijaya Reddy
Alexandra Borst
Monroe Carell Junior Children's Hospital at Vanderbilt
Author Profile
Christopher Bonfield
Monroe Carell Junior Children's Hospital at Vanderbilt
Author Profile
Poornachanda Deenadayalan
Vanderbilt University
Author Profile
Chi Le
Vanderbilt University School of Medicine
Author Profile
Meng Xu
Vanderbilt University School of Medicine
Author Profile
Jenna Sobey
Monroe Carell Junior Children's Hospital at Vanderbilt
Author Profile
Srijaya Reddy
Monroe Carell Junior Children's Hospital at Vanderbilt
Author Profile

Abstract

INTRODUCTION: Children undergoing complex cranial vault reconstruction (CCVR) for craniosynostosis experience high rates of bleeding and transfusion, increasing risk for perioperative complications. ε-Aminocaproic acid (EACA) and tranexamic acid (TXA) are antifibrinolytic agents that have been shown to reduce intraoperative hemorrhage and transfusion requirements during CCVR. However, the relative efficacy of these two agents has not yet been evaluated. The aim of this study was to compare perioperative blood loss and transfusion rates in children receiving EACA vs. TXA. METHODS: All patients who underwent CCVR from September 2015 to December 2019 at a single center were retrospectively evaluated. Primary outcome measures included intraoperative estimated blood loss, postoperative drain output, transfusion volumes, and calculated blood loss. Secondary outcome measures included hematologic and coagulation parameters. RESULTS: 95 patients were included, with 47 patients in the EACA cohort and 48 patients in the TXA cohort. There were no significant differences in demographics, surgical outcomes, blood loss, transfusion requirement, or perioperative hematologic and coagulation laboratory values between the two cohorts. Adverse events were similar between the groups, but did include two seizure events and two thromboembolic events related to vascular access devices. DISCUSSION: We found no significant difference in blood loss, transfusion requirements, hematologic parameters, or outcomes between pediatric CCVR patients who received EACA vs. TXA. Further research is needed to define optimal antifibrinolytic dosing and duration of therapy. While standard laboratory parameters were similar between groups, future studies investigating coagulation-based and inflammatory assays may be useful in defining surgical-induced coagulopathy.